Cristina B. Guzmán

Treatment with <scp>LY</scp> 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Cristina B. Guzmán, Xiaotian Michelle Zhang, Rong Liu et al. · Diabetes Obesity and Metabolism · 2017 · 165 citations

Medicine, Endocrinology, Pharmacology +17

Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study

Jean‐François Yale, Hélène Dulude, Marc Egeth et al. · Diabetes Technology & Therapeutics · 2017 · 88 citations · Full text

Medicine, Internal Medicine, Diabetology +16

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting

Elizabeth R. Seaquist, Hélène Dulude, Xiaotian Michelle Zhang et al. · Diabetes Obesity and Metabolism · 2018 · 54 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setti

Larry C. Deeb, Hélène Dulude, Cristina B. Guzmán et al. · Pediatric Diabetes · 2018 · 50 citations · Full text

Medicine, Endocrinology, Pediatrics +17

Treatment with the glucagon receptor antagonist <scp>LY2409021</scp> increases ambulatory blood pressure in patients with type 2 diabetes

Christof Kazda, Juan P. Frías, Irene Foga et al. · Diabetes Obesity and Metabolism · 2017 · 38 citations

Medicine, Pharmacology, Pharmacotherapy +13